Ruptured and Unruptured Intracranial Aneurysms
Conditions
Brief summary
Flow disruption is a new endovascular approach for treatment of both ruptured and unruptured intracranial aneurysms, which involves placement of an endosaccular device (WEB) which modifies the blood flow at the level of the neck and induces intraaneurysmal thrombosis. The WEB was designed to treat wide-neck bifurcation aneurysms. This observational study will collect data about the routine practice in one center of using the WEB in ruptured and unruptured intracranial aneurysms. The primary objective is to evaluate its efficacy by assessing the anatomic outcome during follow-up.
Interventions
The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/iridium radiopaque markers.
Sponsors
Archer Research
Medical Therapy Solutions
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patient is between 18 and 80 years old. * Patient must sign and date the informed consent form \<72hrs post-procedure and prior to data registration. If patient is not able to give informed consent for himself/herself, a legally authorized representative must give informed consent on his/her behalf. * Patient has a ruptured (Hunt and Hess grades 1, 2 or 3) or unruptured intracranial aneurysm requiring endovascular treatment. * Aneurysm with dome-to-neck ratio ≥ 1.
Exclusion criteria
* Aneurysm size unfavourable for WEB implantation (aneurysm width \> 10 mm or aneurysm width \< 3mm). * Patient with Hunt and Hess grades 4 or 5. * Known to be, or suspected of being unable to comply with the study protocol (e.g. no permanent address, known to be non-compliant or presenting an unstable psychiatric history). * Parent vessel occlusion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determination of anatomic outcome: grade of occlusion of the aneurysm assessed by MRA | at 6 months follow-up | WEB Occlusion Scale: WOS A: complete occlusion WOS B: complete occlusion with opacification of the proximal recess WOS C: residual neck filling WOS D: residual aneurysm filling |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Recording the use of additional devices during treatment to occlude the aneurysm | During index-procedure | Possible additional devices are stent, coils, flow diverter |
| Determination of the occurrence of post-procedural symptomatic thromboembolic events | up to 24 months follow-up | — |
| Determination of clinical outcome: assessing disability of the patient by the modified Rankin Scale (mRS) | at 6 to 8 weeks follow-up | 0 - No symptoms. 1. \- No significant disability. Able to carry out all usual activities, despite some symptoms. 2. \- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. \- Moderate disability. Requires some help, but able to walk unassisted. 4. \- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. \- Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. \- Dead. |
| Determination of the technical success of the device defined as device deployment in the target aneurysm as intended by the investigator with complete apposition against the aneurysm wall. | During index-procedure | — |
| Determination of procedural complications (Adverse events) during the operation | During index-procedure | Procedural complications: aneurysm rupture, dissection, thromboembolic events (symptomatic and non-symptomatic), device protrusion through the neck of the aneurysm inside the parent artery, detachment problem, device stuck in microcatheter, bleeding. |
| Determination of overall mortality | up to 24 months | — |
| Recording of intracranial haemorrhage during follow-up | up to 24 months | — |
| Need for repeat treatment during follow-up | up to 24 months | — |
| Determination of 30 day mortality | up to 30 days | — |
Countries
Belgium
Outcome results
None listed